ClinicalTrials.gg

Program

SEP-380135

A development code. Also written as “14C-SEP-380135”.

Its studies are mostly in Schizophrenia, led by Otsuka.

Furthest: phase 1, since Dec 12, 20253 company-led studies, 1 open or runningNext primary completion: Dec 2, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka31 open or runningphase 1since Dec 12, 2025Dec 12, 2025Dec 2, 2026phase 1 · NCT07455084

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2025First study: phase 1 study in SchizophreniaFirst studyNCT07305779 · 12 enrolled · United States
  2. Mar 3, 2026Phase 1 study in SchizophreniaNCT07455084 · 8 planned · United States
  3. Apr 17, 2026Phase 1 study in SchizophreniaNCT07549581 · 43 enrolled · United States
  4. Oct 16, 2026Primary completion moved from 2026-04-10 to 2026-12-02Date moved laterphase 1 · +8 months · NCT07455084

Ahead

  1. Dec 2, 2026Primary completion: phase 1 study in SchizophreniaNCT07455084

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07549581Schizophrenia · United States1CompletedSep 12, 202543
NCT07455084Schizophrenia · United States1Not yet recruitingDec 2, 20268
NCT07305779Schizophrenia · United States1CompletedMay 3, 202512

How it is read

Names in the registry

  • “SEP-380135”, 2 entries
  • “14C-SEP-380135”, 1 entry

Codes read as this program: SEP380135.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.